Despite the latest technical progress, external radiotherapy treatment can produce cutaneous adverse reactions ranging from simple redness to severe burns.
A patient’s reactions depend on the irradiated area, the dosage delivered, how the therapy is broken down, the type of radiation (particularly electron beams), the energy level (especially cobalt) and sometimes the individual susceptibility of the patient.
The cutaneous adverse reactions of irradiation remain a concern for patients, doctors and carers alike due to their frequency and early appearance during radiation treatment which can hinder and even interrupt treatment with potential repercussions on its efficacy.
Even if it is not always major, this early skin damage due to radiation can interfere with the quality of life of the patient not only due to its actual presence (a source of pain and discomfort) but also to its possible impact on the treatment procedure.Cutaneous adverse reactions can occur immediately or some time after irradiation.
For preventive or curative action, we have developed EVOSKIN® Repair gel cream which we recommend using two weeks before radiation therapy begins in order to reduce the reactiveness of the skin.
EVOSKIN® is a dermocosmetic product designed to soothe skin damage such as redness, stinging and irritation, and even intense burns caused by various types of external factors (excessive sun exposure, radiation therapy, dermatological laser procedures, chemical peeling, etc.).
It should be noted that EVOSKIN® Repair exhibits very good compatibility with the pH of the skin because it is in the vicinity of 6, the average value observed on the skin’s surface.
As part of its research to develop cancer supportive care, EVAUX ®has conducted a comparative study on the prevention of radio-dermatitis between EVOSKIN® Repair and DEXERYL® in the radiation therapy department of Poitiers Teaching Hospital run by Professor Bensadoun which shows a significant advantage for EVOSKIN® with respect to the first signs of radio-dermatitis which are delayed for two weeks using EVOSKIN® as compared with DEXERYL®.
It thus has a soothing effect on both the intensity of stinging and its average duration, which is reduced from 15 to 1 minute*.
In the long term, tolerance to irritants is greatly improved, which is an advantage in preventing damage caused by therapy procedures in particular.
According to an assessment carried out under dermatological control, after 4 weeks of treatment, the cutaneous reactivity evaluated by the stinging test was reduced significantly by 82%*.
**22 patients aged 19 to 39 years presenting with skin sensitivity on the face. 28-day study. Twice-daily application.
Download results of clinical trial